ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status:
Completed
Trial end date:
2019-03-25
Target enrollment:
Participant gender:
Summary
This is an open-label dose escalation study designed to evaluate the safety and
pharmacokinetics of ABBV-085 and determine the recommended Phase 2 dose (as monotherapy or in
combination with standard therapies) in subjects with advanced solid tumors.